Author Archives: abcuro

Abcuro to Present Late-Breaking Abstract at American College of Rheumatology Convergence 2021 of ABC008 Inclusion Body Myositis Phase 1 Data Demonstrating Proof of Mechanism for Selective Depletion of Highly Cytotoxic T Cells

ABC008 is a first-in-class monoclonal antibody designed to selectively deplete highly cytotoxic T cells ABC008 offers therapeutic potential across a broad range of diseases in addition to inclusion body myositis, such as T cell large granular lymphocytic leukemia (T-LGLL) and mature … Read More

Abcuro Appoints Darlene Deptula-Hicks to its Board of Directors

Newton, Massachusetts, October 19, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced the appointment of Darlene Deptula-Hicks as a member of the company’s … Read More

Abcuro to Present Trial in Progress Poster on a Phase 1 Clinical Trial of ABC008 Demonstrating Targeted Depletion of Large Granular Lymphocytes at the 2021 Leukemia, Lymphoma and Myeloma Congress

Newton, MA, October 6, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells, today announced that a Trial in Progress poster describing a Phase 1 trial … Read More

Abcuro and ImaginAb Share Initial Results of Study Using Novel Technology for Imaging T Cell Infiltration of Skeletal Muscle in Patients with Inclusion Body Myositis

Study sponsored by ImaginAb supports hypothesis that CD8+ T cells are present throughout the skeletal muscle system in inclusion body myositis  Proprietary ImmunoPET technology developed by ImaginAb provides a more comprehensive view of T cell infiltration than offered by muscle … Read More

Abcuro Appoints Niti Goel, M.D., as Chief Medical Officer

Clinical leader brings deep expertise in clinical development, medical and regulatory affairs Newton, MA, June 2, 2021– Abcuro, Inc., a clinical-stage biotechnology company developing therapies for autoimmune diseases and cancer through precise modulation of cytotoxic T and NK cells today … Read More

Abcuro Raises $42 Million in Series A-1 Financing, Appoints John B. Edwards as Executive Chair of the Board of Directors and David de Graaf, Ph.D. as Chief Executive Officer

Financing round led by Mass General Brigham Ventures and Sanofi Ventures Proceeds to support advancement of the lead autoimmune program into clinical development, as well as further development of the company’s pipeline  Newton, MA, January 7, 2021– Abcuro, Inc., a … Read More

Abcuro Granted Orphan Drug Designation for ABC008 for Inclusion Body Myositis

Inclusion body myositis (IBM)is an autoimmune condition in which cytotoxic T cells chronically attack muscle cells, leading to progressive weakness and severe disability Abcuro’s lead program, ABC008, is an anti-KLRG1 antibody capable of depleting highly differentiated cytotoxic T cells that … Read More

Abcuro Founder Reports on the Role of KLRG1+ T cells in Inclusion Body Myositis

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in inclusion body myositis (IBM), titled “Highly Differentiated Cytotoxic T Cells in Inclusion Body Myositis”. IBM is an autoimmune disease characterized by T cell infiltration and attack … Read More

Abcuro Founder Reports on the Role of KLRG1+ T cells in Primary Billiary Cholangitis

Abcuro co-founder Steven A Greenberg, MD and his collaborators have published results of studies on clinical samples in primary biliary cholangitis (PBC), titled “Cytotoxic KLRG1 Expressing Lymphocytes Invade Portal Tracts in Primary Biliary Cholangitis”. PBC is an autoimmune disease characterized by T cell … Read More

National Cancer Institute Awards SBIR Grant to Advance Development of KLRG1 Targeted Therapy for Melanoma

Abcuro Inc., announced that it has been awarded a Small Business Innovation Research Grant (SBIR) from the NIH National Cancer Institute. This Phase I grant will support advancement of the company’s anti-KLRG1 blocking antibody (ABC-015) with support for testing in … Read More